Rekombinanter IL-15 Antikörper

Produktnummer ABIN7488621

Der Maus Monoklonal Anti-IL-15-Antikörper wurde für ELISA validiert. Er ist geeignet, IL-15 in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter IL-15 Antikörper (ABIN7488621)

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser IL-15 Antikörper ist unkonjugiert

Applikation: ELISA

Klon: 12B11E5

Produktdetails anti-IL-15 Antikörper

Verwendungszweck: Anti-Human IL15 (12B11E5) mAb, Mouse IgG1

Immunogen: Anti-Human IL15 (12B11E5) MAb, Mouse IgG1 is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a Mouse monoclonal antibody with mouse IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with IL15.

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Lagerung: -20 °C

Details zu IL-15

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Andere Bezeichnung: IL15

Hintergrund: Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells, cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Pathways: JAK-STAT Signalweg, Glycosaminoglycan Metabolic Process